### PATENT COOPERATION TREATY

# **PCT**

### INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference U180.12PC.11	FOR FURTHER See Notification of (Form PCT/ISA/2	of Transmittal of International Search Report 220) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/IB 03/00332	09/01/2003	09/01/2002
Applicant	<u> </u>	•
UNIVERSITY OF LAUSANNE		
This International Search Report has been eccording to Article 18. A copy is being tra	n prepared by this International Searching Aut ansmitted to the International Bureau.	nority and is transmitted to the applicant
This International Search Report consists  It is also eccompanied by	of a total of sheets. e copy of each prior art document cited in this	report.
Basis of the report		
e. With recerd to the language, the	international search was carried out on the bas less otherwise indicated under this item.	sis of the international epplication in the
Authority (Rule 23.1(b)).	ras carried out on the basis of a translation of t	
was carried out on the basis of the	d/or amino ecid sequence disclosed in the in e sequence listing: onal application in written form.	nternational application, the international search
🖵	ernational application in computer readable for	m,
<u> </u>	this Authority in written form.	
X furnished subsequently to	this Authority in computer readble form.	
X the statement that the sub international application a	bsequently furnished written sequence listing d as filed has been furnished.	loes not go beyond the disclosure in the
X the statement that the info furnished	rmation recorded in computer readable form is	s identical to the written sequence listing hes been
	and unsearchable (See Box I).	
3. X Unity of Invention is lac	king (see Box II).	
4. With regard to the title,		
X the text is approved as su	ubmitted by the applicant.	
the text has been establis	shed by this Authority to read as follows:	
5. With regard to the abstract,	A	
X the text is approved as su the text has been establis within one month from the	ubmitted by the applicant. Shed, according to Rule 38.2(b), by this Authori e date of mailing of this international search rep	ity as it appears in Box III. The applicant may, port, submit comments to this Authority.
6. The figure of the drawings to be pub	lished with the abstract is Figure No.	
as suggested by the appl	icant.	X None of the figures.
because the applicant fai		
because this figure better	r characterizes the invention.	

Form PCT/ISA/210 (first sheet) (July 1998)

	International Application No. PC 17	1B 03/00332
FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210		
Continuation of Box I.1		
As far as claims 25-30 are directed to a met human/animal body, the search has been carri alleged effects of the compound/composition.	hod of treatment of the ed out and based on the	
8		

International application No. PCT/IB 03/00332

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.:  Claims Nos.:  Claims Nos.:  As far as claims 25-30 are directed to a method of treatment of the
human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.:     Decause they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims Nos.:      because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box ii Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-7, 17-30 (completely); 8-19 (partially)
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-7, 17-30 completely, 8-10 partially

peptides comprising sequence of Seq ID No. 2 i.e. the sequence SX[SP]V[GL]XPPSRP, nucleic acid encoding it, the vector comprising the nucleic acid, and the cell comprising the vector, composition comprising the peptide and methods using peptide. This includes peptides comprising sequence of Seq ID No. 5, i.e. the sequence SXSVGX covalently linked to sequence of Seq ID No. 36, i.e. the sequence XRKKRRQRRX

2. claims: 8-10 partially

peptides comprising sequence of Seq ID No. 6, i.e. the sequence PPSPRP covalently linked to sequence of Seq ID No. 36, i.e. the sequence XRKKRQNRRX and peptides comprising the sequences of Seq ID Nos 7-11 having a common SPR core sequenceas far as they do not fall under scope of an invention mentioned above

3. claims: 8-16 partially

peptides comprising the sequence of Seq ID No. 12, i.e. GQPFFSPFS as far as they do not fall under scope of an invention mentioned above

4. claims: 8-16 partially

peptides comprising the sequence of Seq ID No. 14, i.e. SPPSNL as far as they do not fall under scope of an invention mentioned above

5. claims: 8-16 partially

peptides comprising the sequence of Seq ID No. 15, i.e. FMPMSSKPSLL as far as they do not fall under scope of an invention mentioned above

6. claims: 8-16 partially

peptides comprising the sequence of Seq ID No. 16, i.e. NASVGNDHSHSH as far as they do not fall under scope of an invention mentioned above

7. claims: 8-16 partially

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

peptides comprising the sequence of Seq ID No. 17, i.e. EHMALTYPFRP as far as they do not fall under scope of an invention mentioned above

8. claims: 8-10 partially

peptides comprising the sequence of Seq ID No. 22, i.e. the sequence XGVSXS covalently linked to sequence of Seq ID No. 36, i.e. the sequence XKKKRRQRRXX as far as they do not fall under scope of an invention mentioned above

9. claims: 8-10 partially

peptides comprising the sequence of Seq ID Nos 18-21 and 23-28 having the core sequence RPS covalently linked to sequence of Seq ID No. 36, i.e. the sequence XRKKRQRRRRX as far as they do not fall under scope of an invention mentioned above

10. claims: 8-10 partially

peptides comprising the sequence of Seq ID No. 29, i.e. the sequence SFPSFFPQG covalently linked to sequence of Seq ID No. 36, i.e. the sequence XRKKRRQRRRX as far as they do not fall under scope of an invention mentioned above

11. claims: 8-10 partially

peptides comprising the sequence of Seq ID Nos 30-31, i.e. the sequence LNSPP covalently linked to sequence of Seq ID No. 36, i.e. the sequence XRKKRRQRRRX as far as they do not fall under scope of an invention mentioned above

12. claims: 8-10 partially

peptides comprising the sequence of Seq ID No. 32, i.e. the sequence LLSPKSWPNF covalently linked to sequence of Seq ID No. 36, i.e. the sequence XRKKRRQRRX as far as they do not fall under scope of an invention mentioned above

13. claims: 8-10 partially

peptides comprising the sequence of Seq ID No. 33, i.e. the sequence HSHSDNGVSAN covalently linked to sequence of Seq ID No. 36, i.e. the sequence XRKKRRQRRX as far as they do not fall under scope of an invention mentioned above

14. claims: 8-10 partially

page 2 of 3

			_
FURTHER INFORMATION CONTINUED FROM	PCT/ISA/	210	

peptides comprising the sequence of Seq ID No. 34, i.e. the sequence PRFPYILANHG covalently linked to sequence of Seq ID No. 36, i.e. the sequence XRKKRRQRRX as far as they do not fall under scope of an invention mentioned above

International Application No PCT/IB 03/00332

A. CLASSIFICATION OF SUBJECT MATTER
I PC 7 C07K14/47 A61K38/17 A61P5/48 A61P25/00

C12N5/10

C12N15/12

C12N15/63

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Flectronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, Sequence Search, CHEM ABS Data

C. DOCUM	ENTS CONSIDERED TO	RE HELEVANI

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	WO 01/27268 A (UNIV LAUSANNE ; BONNY CHRISTOPHE (CH) 19 April 2001 (2001-04-19) the whole document	1-10, 17-30
X	BONNY C ET AL: "Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death." DIABETES. JAN 2001, vol. 50, no. 1, January 2001 (2001-01), pages 77-82, XP602274267 ISSN: 0012-1797 the whole document	1-10, 17-30
P,A	WO 02/081504 A (UNIV JEFFERSON) 17 October 2002 (2002-10-17) see Seq 1D NO 9 in table 1; Claim 5; table 1	11-14,16
1	-/	

X Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or
- Date of the actual completion of the international search
- "P" document published prior to the international filing date but later than the priority date claimed
- T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "V" document of particular relevance; the claimed invention carnot be considered to involve an inventive step when the document is combined with one or more other such docu-ments, such combination being obvious to a person skilled in the art.

19 07 2004

"A" document member of the same natent family

Date of mailing of the International search report

30 March 2004

Authorized officer

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3018

Fuhr, C

Form PCT/ISA/210 (second sheet) (January 2004)

page 1 of 2

4

International Application No PCT/IB 03/00332

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category \* | Citation of document, with Indication, where appropriate, of the relevant passages Relevant to claim No. WO 02/081505 A (WIESEHAN KATJA; WILLBOLD DIETER (DE); IMB INST FUER MOLEKULARE BIOTE) 17 October 2002 (2002-10-17) see peptide SVSVGMKPSPRP in figure 1figure 11-16 P.A

Information on patent family members

International Application No PCT/IB 03/00332

					,	03/00332
Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0127268	Α	19-04-2001	US	6610820		26-08-2003
			ΑU	7938200		23-04-2001
			CA	2387184		19-04-2001
			EP	1303600		23-04-2003
			WO	0127268		19-04-2001
			JP	2003511071		25-03-2003
			US	2003220480		27-11-2003
			US	2004082509		29-04-2004
			US	2002127676		12-09-2002
			US	2003108539	A1	12-06-2003
WO 02081504	Α	17-10-2002	CA	2442909	A1	17-10-2002
			EP	1373308	A2	02-01-2004
			WO	02081504	A2	17-10-2002
			US	2003013844	A1	16-01-2003
			US	2004086512	A1	06-05-2004
WO 02081505		17-10-2002	DE	10117281	A1	24-10-2002
MO 05001303	^	1, 10 2002	WO	02081505		17-10-2002
			ĒΡ	1379546		14-01-2004